Pinterest • The world’s catalogue of ideas

Erlocip (Erlotinib Tablets) Erlocip (Erlotinib) is an anti-cancer medication which works by blocking the epidermal growth factor receptor (EGFR). Thi

#LungCancer #NonSmallCellLungCancer #CancerResearch With the new cobas Epidermal Growth Factor Receptor test, doctors at some public hospitals are now able to detect the presence of gene mutations. About half of non-small cell lung cancer is linked to a genetic epidermal growth factor receptor (EGFR) mutation - affecting mostly female non-smokers.

Erbitux is for head and neck cancer as well as metastasized colon cancer. It works by inhibiting the EGFR receptor, a growth factor receptor in the epidermal tissues. This keeps the cancerous cells from growing.

New breast cancer test could spare women chemotherapy

Thousands of women with breast cancer could be spared chemotherapy following NHS approval of a test which can help establish who needs the treatment and who might not...the oncotype DX test, was approved for women who have oestrogen receptor positive (ER+), lymph node negative (LN–) and human epidermal growth factor receptor 2 negative (HER2–) in early breast cancer..

pin 2

EGFR stains using the DakoCtomation kit on colon carcinomas. Nonspecific cytoplasmic staining (left) is common, and should be ignored. -

pin 1

EGFR immunostains performed with the DakoCytomation kit. Note staining of prostate basal cells (upper left), placenta (upper right), chromophobe renal cell carcinoma (lower left), and lung adenocarcinoma (lower right).-

pin 1

Iressa is the international trade name for Gefitinib 250mg tablets that is manufactured by Astrazeneca Pharmaceuticals. Gefitinib 250 mg Iressa belongs to a class of anti-cancer medications called Epidermal Growth Factor Receptor (EGFR) tyrosine kinaseinhibitors. Get Iressa Price which medicine used for the treatment of non-small cell lung cancer. By keeping track with the latest market development, Anti Cancer Aid introducing high quality of Pha

Nov 2015- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.